Christoph Sarrazin
Overview
Explore the profile of Christoph Sarrazin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
288
Citations
6840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Razavi H, Waked I, Qureshi H, Kondili L, Duberg A, Aleman S, et al.
J Hepatol
. 2025 Feb;
PMID: 39914746
Background And Aims: The year 2023 marked the 10-year anniversary of the launch of direct-acting antivirals (DAAs) for the treatment of the hepatitis C virus (HCV). HCV treatment trends by...
2.
Schafer N, Rothhaar P, Heuss C, Neumann-Haefelin C, Thimme R, Dietz J, et al.
Viruses
. 2025 Jan;
16(12.
PMID: 39772180
The study of hepatitis C virus (HCV) replication in cell culture is mainly based on cloned viral isolates requiring adaptation for efficient replication in Huh7 hepatoma cells. The analysis of...
3.
Buitkamp S, Schwalm S, Jakobi K, Ferreiros N, Wunsche C, Zeuzem S, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596241
Sphingolipids play a major role in the regulation of hepatocellular apoptosis and proliferation. We have previously identified sphingolipid metabolites as biomarkers of chronic liver disease and hepatocellular carcinoma. Human hepatocellular...
4.
Graf C, Sarrazin C, Dietz J
JHEP Rep
. 2024 Nov;
6(12):101197.
PMID: 39583093
No abstract available.
5.
Cornberg M, Huppe D, Sarrazin C, Ahumada A, Jorquera Plaza F, Marino Z, et al.
Adv Ther
. 2024 Oct;
41(12):4669-4682.
PMID: 39470876
Introduction: This brief report presents updated findings from the previously published CREST study evaluating the safety and effectiveness of 8-week glecaprevir/pibrentasvir (GLE/PIB) in treatment-naïve patients with chronic hepatitis C virus...
6.
Wiegand J, Franke A, Muller T, Stein K, Bantel H, Gunther R, et al.
Z Gastroenterol
. 2024 Sep;
62(11):1931-1942.
PMID: 39227008
Real-world data on the management of patients with primary biliary cholangitis (PBC) are so far scarce in Germany. Therefore, we aimed to establish a nationwide registry and describe the clinical...
7.
Schmitt A, Sarrazin C
Dtsch Med Wochenschr
. 2024 Aug;
149(16):955-961.
PMID: 39094600
Chronic infection with hepatitis C virus (HCV) is a common cause of complications such as liver cirrhosis and hepatocellular carcinoma (HCC). It is one of the most significant infectious diseases...
8.
Basic M, Thiyagarajah K, Glitscher M, Schollmeier A, Wu Q, Gorgulu E, et al.
Liver Int
. 2024 Jul;
44(10):2773-2792.
PMID: 39078064
Background: The hepatitis B e antigen (HBeAg)-negative infection Phase 3 is characterized by no or minimal signs of hepatic inflammation and the absence of hepatic fibrosis. However, underlying molecular mechanisms...
9.
Dietz J, Graf C, Berg C, Port K, Deterding K, Buggisch P, et al.
JHEP Rep
. 2024 Jul;
6(7):101072.
PMID: 39006503
Background And Aims: Data on the prevalence and characteristics of so-called rare HCV genotypes (GTs) in larger cohorts is limited. This study investigates the frequency of rare GT and resistance-associated...
10.
Durmashkina E, Sarrazin C, Nitschmann S
Inn Med (Heidelb)
. 2024 May;
65(7):746-748.
PMID: 38748277
No abstract available.